Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment
Allergologia et Immunopathologia · 01.03.2026 · 54 (2) · 51-56
DOI: 10.15586/aei.v54i2.1545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergologia et Immunopathologia, online erschienen am 01.03.2026. Verfasst von Hatice Çelik Tuğlu und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Health Sciences Atatürk Sanatoryum Training and Research Hospital, Division of Immunology and Allergy, Department of Chest Diseases, An…. Hauptthemen laut MEDLINE: Asthma, Omalizumab, Eosinophils, Antibodies, Monoclonal, Humanized. Gefördert von: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors..
Abstract (Originalsprache)
Introduction
Identifying the eosinophilic, neutrophilic, or infectious phenotypes of exacerbations, particularly those occurring during biologic agent therapy, may provide valuable guidance for determining maintenance therapy for patients and preventing recurrent exacerbations. Our study primarily aimed to evaluate the clinical phenotypic features of exacerbations in patients with severe asthma receiving biologic agent therapy.
Methods
The first asthma exacerbation experienced by the patients after the 16th week of biological agent treatment was evaluated in terms of inflammatory phenotype and clinical features. White blood cell counts and C-reactive protein levels, related season, antibiotic use, and hospitalization during the exacerbation were recorded from patients’ medical file records.
Results
Data of 75 patients with severe asthma receiving biological treatment were analyzed. Subjects were aged 48.0 (mean) ± 11.0 (standard deviation), and 52 (69.3%) of them were female. Biological agent used in treatment was omalizumab in 53 (70.7%) subjects and mepolizumab in 22 (29.3%) subjects. The majority of exacerbations in asthmatics treated with either biologic agent were eosinophilic. In patients using omalizumab, the median eosinophil count was significantly higher compared to those using mepolizumab (p=0.032).
Conclusion
Phenotyping of asthma exacerbations that persist in spite of biologic therapy will guide treatment adjustments and decisions to switch biologic agents to improve outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Health Sciences Atatürk Sanatoryum Training and Research Hospital, Division of Immunology and Allergy, Department of Chest Diseases, Ankara, Turkiye.
- University of Health Sciences Atatürk Sanatoryum Training and Research Hospital, Division of Immunology and Allergy, Department of Chest Diseases, Ankara, Turkiye; kurtulusaksu@yahoo.com.
- University of Health Sciences Atatürk Sanatoryum Training and Research Hospital, Department of Chest Diseases, Ankara, Turkiye.
Förderung
- This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Zitieren
APA
Tuğlu, H. Ç., Aksu, K., Akkale, Ö., Telli, O., Çelik, F. D., Yağdıran, M., Göktürk, Ö., Solak, G. T. V., & Aksu, F. (2026). Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment. Allergologia et Immunopathologia, 54(2), 51-56. https://doi.org/10.15586/aei.v54i2.1545
Vancouver
Tuğlu HÇ, Aksu K, Akkale Ö, Telli O, Çelik FD, Yağdıran M, et al. Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment. Allergologia et Immunopathologia. 2026;54(2):51-56. doi:10.15586/aei.v54i2.1545
BibTeX
@article{Tulu2026,
author = {Tuğlu, Hatice Çelik and Aksu, Kurtuluş and Akkale, Özgür and Telli, Onur and Çelik, Fatma Dindar and Yağdıran, Melis and Göktürk, Özge and Solak, Gürgün Tuğe Vural and Aksu, Funda},
title = {Phenotypic characteristics of exacerbations in severe asthmatics receiving biological agent treatment},
journal = {Allergologia et Immunopathologia},
year = {2026},
volume = {54},
number = {2},
pages = {51--56},
doi = {10.15586/aei.v54i2.1545}
}
EUVIMED